Other relevant news · Mind Medicine Australia
Mind Medicine Australia logo Menu

Other relevant news

How Psychedelics Could Help Soldiers Overcome Trauma

Time, March 10, 2024

Amid this mental health catastrophe, authorities have begun turning to psychedelics for help—and for good reason.

Single dose of LSD provides immediate and lasting relief from anxiety, study says

CNN, March 7, 2024

A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder.

Thanks to this man, MDMA could soon be legal for therapy

The Guardian, March 1, 2024

Rick Doblin is a psychedelic pioneer – and he thinks it can help us save the world, one trauma-ending trip at a time.

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Incannex Healthcare, February 28, 2024

Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder (GAD). The trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.

How Psychedelics Could Become The Medicine Of The Future

The Project, February 28, 2024

Australian researchers are revolutionising mental health treatment, with the country becoming the first to legalise the use of psychedelics as treatment.

Shannon is terminally ill. In a trailblazing trial, she took a white pill

The Sydney Morning Herald, February 24, 2024

In a groundbreaking Australian study, Shannon Turner and 34 other terminally ill patients used psychedelics for their end-of-life treatment. They lift the lid on what it was like.

Read the full PDF article here.

Mind Medicine Australia is proud to be a part funder of the St Vincent’s trial.

Exercise twice as effective as antidepressants

The Telegraph, February 15, 2024

Exercise is twice as effective at treating depression as antidepressants, a study has suggested.

Read the PDF article here.

Read the full research study here.

ISRAELI GROUP TO STUDY MDMA THERAPY FOR OCTOBER 7 SURVIVORS WITH PTSD

The Intercept, February 14, 2024

The patients would undergo two sessions with the drug each in small groups, in what would be the largest MDMA-assisted therapy study anywhere to date — a milestone in the passage of psychedelic medicine into mainstream acceptance.

Psychedelics may help treat PTSD—and the VA is intrigued

National Geographic, February 13, 2024

Demand from veterans for psychedelic medicine is poised to explode as research suggests it might help with post-traumatic stress disorder and depression.

Read the full PDF here.

First patient to be dosed with psychedelic drugs hails the therapy

The Australian, February 12, 2024

Claire Danko never intended to make medical history. The 38-year-old Melbourne woman, who for years had suffered debilitating symptoms of post-traumatic stress disorder, just wanted mental relief.

Read the full PDF here.

New Study Links Psychedelic Experiences To Better Sex

Forbes, February 8, 2024

Psychedelics including psilocybin and LSD may improve sexual function for months after a psychedelic experience, according to a new study from researchers at Imperial College London.

Reckoning looms for depression drugs

The Australian, January 28, 2024

The world’s first psychiatry guidelines on de-prescribing antidepressants have sparked a fierce debate in medicine as the debunked ‘chemical imbalance’ theory comes under scrutiny.

Read the full PDF here.

EU to Fund Study of Psilocybin for Patients in Palliative Care

Filter Magazine, January 26, 2024

The European Union is putting money into a psychedelic study with patients who are receiving palliative care for incurable illnesses.

European Union Funds Groundbreaking Research Into Psychedelic Therapy

Open Foundation, January 24, 2024

A European consortium of 19 partners has been awarded over €6.5M by the European Union to study psilocybin to treat psychological distress in people with progressive incurable illnesses requiring palliative care.

Australian psychiatrist co-authors first antidepressant deprescribing guidelines

The Australian, January 22, 2024

Growing disquiet about the over prescription of antidepressants has been acknowledged in the first guidelines on deprescribing, with doctors being told the benefits of the drugs will be outweighed in some patients by adverse effects.

Field trip: inside America’s first magic mushroom school

The Guardian, January 14, 2024

At a forest facility in Oregon, the first US state to allow supervised use of the medicine, students work toward becoming licensed trip facilitators.

Israel is at the vanguard of a new psychedelic revolution

Wired, December 18, 2023

More than 50 years after the psychedelic revolution, Israeli startups are proving to be pioneers in the use of mind-altering drugs—from mushrooms to medical-grade cannabis—to treat conditions like depression and PTSD.

Health Benefits Provider Will Cover Psilocybin-Assisted Therapy In States Where It’s Legal

Marijuana Movement, December 15, 2023

A Massachusetts company that bills itself as “the first and only licensed provider of psychedelic health plans” announced on Tuesday that it will cover psilocybin-assisted therapy in states where it’s legal.

MDMA-Assisted Therapy for PTSD Edges Toward Acceptance – When Might It Be Approved?

Psychedelic Spotlight, December 13, 2023

If approved, MDMA-AT would be the first psychedelic-assisted therapy procedure for PTSD.

Read the full MAPS press release here.

FDA to review MDMA-assisted therapy, a milestone for psychedelics

The Washington Post, December 12, 2023

MAPS Public Benefit Corp. filed an application on Tuesday with the U.S. Food and Drug Administration to approve MDMA in combination with therapy to treat post-traumatic stress disorder, in what would be the first treatment of its kind.

Read the full PDF article.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×